Go online to PeerView.com/DYM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the use of antisense oligonucleotide therapies in patients with amyotrophic lateral sclerosis (ALS). Upon completion of this accredited CE activity, participants should be better able to: Identify common genes and cellular processes implicated in ALS pathogenesis, Recognize the mechanisms of action, efficacy, and safety profiles of emerging ALS therapies including antisense oligonucleotides, Discuss how the ALS treatment paradigm may change as a result of emerging therapies, Educate patients with ALS about ongoing clinical trials evaluating novel disease-modifying therapies.

Podden och tillhörande omslagsbild på den här sidan tillhör PVI, PeerView Institute for Medical Education. Innehållet i podden är skapat av PVI, PeerView Institute for Medical Education och inte av, eller tillsammans med, Poddtoppen.